Peptide Therapeutics Market - Forecast(2024 - 2030)
Peptide Therapeutics Market Overview
Peptide Therapeutics Market size is estimated to reach $48.2 billion by 2026, growing at a CAGR of 9.4% during the forecast period 2021-2026. Peptides are short chains of amino acids that perform many roles within the cell, such as anti-infectives and signaling. These therapeutics have the ability to treat various conditions from peptide replacement to antivirals. Peptide therapeutics are increasingly being adopted across the world owing to the rise in the prevalence of gastrointestinal disorders, cancer, and metabolic disorders.
The rise
in the prescription of peptide therapeutics for the treatment of cancer,
increasing adoption of generic peptides for various infectious diseases owing
to its cost-effectiveness, rise in the adoption of peptides as medical
diagnostic devices, and growing investment by the key players to develop
advanced peptide therapeutics are the factors that are set to drive the growth
of the Peptide Therapeutics
Market for the period 2021-2026.
Peptide Therapeutics Market Report Coverage
The
report: “Peptide Therapeutics
Market Forecast (2021-2026)”, by Industry ARC, covers an in-depth analysis
of the following segments of the
Peptide Therapeutics Market.
By
Type: Generic and Branded.
By
Route of Administration: Parenteral,
Oral, and Others.
By
Application: Gastrointestinal Disorders,
Cancer, Metabolic Disorders, Neurological
Disorders, and Others.
By Geography: North
America (U.S., Canada, and Mexico), Europe (Germany, UK, France, Italy, Spain,
Russia, and Rest of Europe), Asia-Pacific (China, India, Japan, South Korea,
Australia & New Zealand, and Rest of Asia-Pacific), South America (Brazil,
Argentina, and Rest of South America) and Rest of World (Middle East and
Africa).
Key Takeaways
- Geographically, North America Peptide Therapeutics Market accounted for the highest revenue share in 2020 and it is poised to dominate over the period 2021-2026 owing to the rise in the adoption of peptides as medical diagnostic devices.
- The cancer category is being driven by an increase in the prescription of peptide therapeutics for cancer care in developing countries. Government regulations, on the other hand, are said to be one of the major factors limiting the growth of the Peptide Therapeutics Market.
- Detailed analysis on the Strength, Weakness, and Opportunities of the prominent players operating in the market will be provided in the Peptide Therapeutics Market report.
For More Details on This Report - Request for Sample
Peptide Therapeutics Market Segment Analysis-By Type
The Peptide Therapeutics Market based on the Type can be further segmented into Generic and Branded. The Branded segment held the largest share in 2020 owing to the factors such as the rise in the number of infectious diseases and the increase in the demand for original products in developed nations. The growing investments by the key players in research and development activities for the development of novel drugs is driving the growth of the Peptide Therapeutics Market.
The Generic segment
is estimated to be the fastest growing segment with a CAGR of 10.6% over the
period 2021-2026. This growth is owing to the factors such as the growing expenditure
on healthcare by the governments, increase in the demand for generic peptides, and
the rise in the product launches by key players.
Peptide Therapeutics Market Segment Analysis-By Application
The Peptide Therapeutics Market based on the Application can be further segmented into Gastrointestinal Disorders, Cancer, Metabolic Disorders, Neurological Disorders, and Others. The Cancer segment held the largest share in 2020 owing to the factors such as increase in the prescription of peptide therapeutics for the treatment of cancer and rise in the investment by the key players to develop advanced peptide therapeutics for cancer treatment.
The rise in awareness among healthcare professionals about the adverse effects of radiation therapy is driving the growth of the Peptide Therapeutics Market. The Metabolic Disorders segment is estimated to be the fastest growing segment with a CAGR of 11.2% over the period 2021-2026. This growth is owing to the factors such as the growing demand for generic peptides for the treatment of metabolic disorders, the rise in the adoption of medical diagnostic devices, and increase in the base of the geriatric population susceptible to metabolic disorders in developed nations.
Peptide Therapeutics Market Segment Analysis-By Geography
North America held the largest
share with 31% of the overall market in 2020. The growth in this segment is
owing to the factors such as the rise in the adoption of peptides as
medical diagnostic devices and the increase in the prescription of peptide
therapeutics for the treatment of cancer.
The rise in the product launches by key players is driving the growth of the Peptide
Therapeutics Market. Asia-Pacific segment is estimated to be the fastest
growing segment over the period 2021-2026. The growth in this segment is owing
to the factors such as the rise in the adoption of generic
peptides for various infectious diseases and growing investment by the key
players to develop advanced peptide therapeutics.
Peptide Therapeutics Market Drivers
Increase in the Prevalence of Metabolic Disorders
Rise in the Adoption of Innovative Platforms to Develop Next-Generation Peptide Therapeutics
Biopharmaceutical
companies are increasingly focusing on innovative platforms to develop
next-generation peptide treatments for immuno-inflammatory diseases. For
instance, companies such as Novo Nordisk A/S and Almirall S.A. are
investing in PolyXen technology, which is a patent-protected platform
technology that develops first-in-class peptide treatments for immuno-inflammatory
diseases, which is one of the major factors driving the growth of the Peptide Therapeutics Market.
Peptide Therapeutics Market Challenges
Stringent Government Regulations
The
key players in the market are collaborating with other players to carry out
various research and development activities for launching advanced generic
peptides for the treatment of various disorders. However, peptide therapeutics
require a better regulatory framework, which is one of the major factors that
is estimated to reduce the growth of the Peptide Therapeutics Market.
Peptide Therapeutics Market Competitive Landscape:
Product launches, mergers and
acquisitions, joint ventures, and geographical expansions are key strategies
adopted by players in the Peptide Therapeutics Market. Key companies of this
market are Eli Lilly and Company, Pfizer Inc, Bachem Holding AG, Takeda
Pharmaceutical Company Limited, Teva Pharmaceutical, Sanofi, Bristol-Myers
Squibb (BMS), GlaxoSmithKline, AstraZeneca PLC, and Novo Nordisk A/S among others.
Acquisitions/Partnerships:
- In March 2021, Takeda Pharmaceutical Company Limited has entered into a partnership with Anima Biotech to discover and develop a new class of peptides and protein drugs for genetically-defined neurological diseases.
- In December 2020, Eli Lilly has acquired Prevail Therapeutics for an aggregate value of up to $1.04Bn to advance its research and development capabilities on peptide-based therapies with the support of the company portfolio of preclinical neuroscience assets.
Relevant Links:
Report
Code: HCR 27424
Report
Code: HCR 22615
For more Lifesciences and Healthcare Market reports, please click here